Jun 13, 2023 / 03:40PM GMT
Paul Choi - Goldman Sachs Group, Inc., Research Division - Equity Analyst
We'll continue with our next session. I'm Paul Choi, and I cover the small and mid-cap biotechnology sector here at Goldman Sachs. It's my pleasure to welcome the management team from Kiniksa. We're joined by, to my left, CEO, Sanj Patel. We also have Dr. John Paolini, CMO, and we have Ross Moat, with commercial.
What we'll do, as we have in prior sessions, is let Sanj get off with some high-level comments. We'll go into Q&A after that. If any audience members along the way have questions, please feel free to raise your hand, and we'll try and get a mic to you. Alternatively, if you're listening on the webcast, please feel free to e-mail us your questions, and I'll read them anonymously. But with that, I'll turn it over to Sanj for some opening comments.
Sanj K. Patel - Kiniksa Pharmaceuticals, Ltd. - CEO & Chairman of the Board
Thank you, Paul. Great to be here. Obviously, we've also got Eben Tessari here, who's our Chief Operating Officer; and Mark Ragosa, who's our
Kiniksa Pharmaceuticals Ltd at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers